You are here

  • Home
  • Online First
  • Potential risk of non-arteritic anterior ischaemic optic neuropathy in semaglutide users: pharmacovigilance insights

Article Text

Article menu
Download PDFPDF
Letter
Potential risk of non-arteritic anterior ischaemic optic neuropathy in semaglutide users: pharmacovigilance insights
  1. Eleonora Castellana
  1. Hospital Pharmacy, Azienda Ospedaliero Universitaria Citta della Salute e della Scienza di Torino, Torino, Piemonte, Italy
    1. Correspondence to Dr Eleonora Castellana; ecastellana{at}cittadellasalute.to.it

    https://doi.org/10.1136/ejhpharm-2024-004333

    Statistics from Altmetric.com

      Request Permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

      An article by Hathaway et al, titled ‘Risk of nonarteritic anterior ischaemic optic neuropathy in patients prescribed semaglutide’,1 was recently published in JAMA Ophthalmology. The authors found that patients taking the glucagon-like peptide-1 receptor agonist (GLP-1 RA) semaglutide for type 2 diabetes or obesity might be at potential risk for non-arteritic anterior ischaemic optic neuropathy (NAION); this condition has an incidence of 2–10 cases per 100 000 individuals, making it the second most common cause of blindness due to optic nerve damage, with glaucoma being the most common.1 Despite the thorough study conducted by the authors, the pathogenesis of NAION remains unclear. The pathology refers to a presumed ischaemic process of the anterior portion of the …

      View Full Text

      Footnotes

      • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

      • Competing interests None declared.

      • Provenance and peer review Not commissioned; internally peer reviewed.